Kabanat 60 mg Injection Kabanat contains Cabazitaxel, a semi-synthetic taxane antineoplastic derivative. It works by binding to tubulin and promoting its assembly into microtubules while simultaneously inhibiting microtubule disassembly. This stabilizes the microtubule network, leading to the inhibition of mitotic and interphase cellular functions, thereby inducing cell cycle arrest and apoptosis in cancer cells. It is indicated, in combination with prednisone or prednisolone, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing regimen.